Modulation of cell proliferation and differentiation of human lung carcinoma cells by the interferon-alpha

General Physiology and Biophysics

Volumn 28, Issue 3, 2009, Pages 294-301

  Krejčová, Daniela ^a,b   Procházková, Jiřina ^a,b   Kubala, Lukáš ^a   Pacherník, Jiří ^b  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

ABC transporter proteins; Cell cycle; Interferons; Non small cell lung cancer

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; ALPHA TUBULIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; STAT1 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LEUKEMIA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MELANOMA; PROTEIN EXPRESSION; TUMOR IMMUNITY;

ALKALINE PHOSPHATASE; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; INTERFERON-ALPHA; LUNG NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 72949121095     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: 10.4149/gpb_2009_03_294     Document Type: Article

References (23)

1. Antoniou K. M., Ferdoutsis E., Bouros D. (2003): Interferons and their application in the diseases of the lung. Chest 123, 209-216; doi: 10.1378/chest. 123.1.209 (Pubitemid 36126734)
2. Barančík M., Boháčová V., Zbýňovcová M., Breier A. (1999): Differential expression of regulatory proteins in L1210/VCR cells with multidrug resistance mediated by P-glycoprotein. Gen. Physiol. Biophys. 18,45-56
3. Bryja V., Pachernik J., Soucek K., Horvath V., Dvorak P., Hampl A. (2004): Increased apoptosis in differentiating p27-deficient mouse embryonic stem cells. Cell. Mol. Life Sci. 61, 1384-1400; doi: 10.1007/s00018-004-4081-4
4. Caraglia M., Marra M., Pelaia G., Maselli R., Caputi M., Marsico S. A., Abbruzzese A. (2005): Alpha-interferon and its effects on signal transduction pathways. J. Cell. Physiol. 202, 323-335; doi:10.1002/jcp.20137
5. Dohadwala M., Luo J., Zhu L., Lin Y, Dougherty G. J., Sharma S., Huang M., Pold M., Batra R. K., Dubinett S. M. (2001): Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem. 276, 20809-20812; doi: 10.1074/jbc.C100140200
6. Frankova J., Kubala L., Velebny V., Ciz M., Lojek A. (2006): The effect of hyaluronan combined with KI3 complex (Hyiodine wound dressing) on keratinocytes and immune cells. J. Mater. Sci. Mater. Med. 17,891-898; doi: 10.1007/S10856-006-0179-6
7. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. (2004): The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv. 1, 27-42; doi:10.2174/ 1567201043480036
8. Hoang T, Traynor A. M., Schiller J. H. (2002): Novel therapies for lung cancer. Surg. Oncol. 11, 229-241; doi:10.1016/S0960-7404(02)00056-57
9. Honma Y, Ishii Y, Yamamoto-Yamaguchi Y, Sassa T, Asahi K. (2003): Cotylenin A, a differentiation-inducing agent, and IFN-a cooperatively induce apoptosis and have an antitumor effect on human non-small cell lung carcinoma cells in nude mice. Cancer Res. 63, 3659-3666 (Pubitemid 36793050)
10. Jonasch E., Haluska F. G. (2001): Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6,34-55; doi: 10.1634/theoncologist.6-1-34
11. Kovarikova M., Pachernik J., Hofmanova J., Zadak Z., Kozubik A. (2000): TNF-a modulates the differentiation induced by butyrate in the HT-29 human colon adenocarcinoma cell line. Eur. J. Cancer 36, 1844-1852; doi:10.1016/S0959- 8049(00)00178-187
12. Kvačkajová-Kišucká J., Barančík M., Breier A. (2001): Drug transporters and their role in multidrug resistance of neoplastic cells. Gen. Physiol. Biophys. 20,215-237
13. Lee J., Jung H. H., Im Y. H., Kim J. H., Park J. O., Kim K., Kim W. S., Ahn J. S., Jung C. W., Park Y.S., Kang W. K., Park K. (2006): Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STATl activation in A549 cells. Oncol. Rep. 15,1541-1549
14. Maione P., Rossi A., Airoma G., Ferrara C., Castaldo V., Gridelli C. (2004): The role of targeted therapy in non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 51, 29-44; doi: 10.1016/j.critrevonc.2004.02.002
15. McCormick C., Freshney R. I., Speirs V. (1995): Activity of interferon alpha, interleukin 6 and insulin in the regulation of differentiation in A549 alveolar carcinoma cells. Br. J. Cancer 71,232-239
16. Mickley L. A., Bates S. E., Richert N. D., Currier S., Tanaka S., Foss R, Rosen N., Fojo A. T. (1989): Modulation of the expression of a multidrug resistance gene (mdr-1/P- glycoprotein) by differentiating agents. J. Biol. Chem. 264, 18031-18040
17. Orlicky J., Sulová Z., Dovinová I., Fiala R., Zahradniková A. Jr., Breier A. (2004): Functional fluo-3/AM assay on P-glycoprotein transport activity in L1210/VCR cells by confocal microscopy. Gen. Physiol. Biophys. 23, 357-366
18. Ozben T. (2006): Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580, 2903-2909; doi:10.1016/j.febslet.2006.02. 020
19. Rius M., Hummel-Eisenbeiss J., Keppler D. (2008): ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4). J. Pharmacol. Exp. Ther. 324,86-94; doi:10.1124/jpet.l07.131342
20. Ruotsalainen T. M., Mattson K. (2002): Interferon trials in small cell lung cancer at one institution: a comparison of results obtained before and after initiation of systematic treatment trials using IFN-alpha in combination with other modalities. J. Interferon Cytokine Res. 22,165-171; doi:10.1089/107999002753536130
21. Sandler A. B. (2003): Molecular targeted agents in non-small-cell lung cancer. Clin. Lung Cancer 5, S22-28; doi: 10.3816/CLC.2003.S.012
22. Sarkadi B., Homolya L., Szakacs G., Varadi A. (2006): Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 86,1179-1236; doi:10.1152/physrev.00037.2005
23. Zarogoulidis K., Ziogas E., Papagiannis A., Charitopoulos K., Dimitriadis K., Economides D., Maglaveras N., Vamvalis C. (1996): Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Lung Cancer 15, 197-205; doi:10.1016/0169-5002(95)00583-588